Strides Arcolab Articles

Pfenex and Agila Biotech set up JV to develop biosimilars

16 April 2013

Malaysian Bio-XCell and Agila Biotech join forces on biotech facility

2 April 2013

GlobalData views potential of Pfizer's rumored acquisition of Strides' Agila unit

20 January 2013

Eli Lilly in deal with Strides Arcolab for cancer drugs in emerging markets

6 December 2012

News briefs: Drug majors eyeing Strides Arcolab unit; Astellas invests in oncology facility

20 August 2012

Gilead partners to provide low-cost emtricitabine-based ARVs in developing countries

3 August 2012

Strides Arcolab unit enters Canada's injectable generics market via JV

16 July 2012

Watson buys Strides Arcolab unit for A$375 million; 2011 results

24 January 2012

Strides Arcolab gets two more cancer generics approved in USA

27 November 2011

Ranbaxy and Mylan unit to make and market three Gilead HIV drugs in developing countries

13 July 2011

India’s Strides Arcolab in deal with Bio-XCell to manufacture in Malaysia

30 June 2011

Pfizer buys Akorn-Strides portfolio of generics for $63 million

4 January 2011

Strides Arcolab raises offer for Ascent's remaining shares to $0.40

24 December 2010

Strides Arcolab expands in biologics, buying 70% stake in Bangalore’s Inbiopro

10 December 2010

Pfizer signs deals with Indian drugmaker Strides Arcolab for generic cancer drugs and niche injectables

17 May 2010

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end